CN106573872B - 5-羟色胺受体靶向化合物和方法 - Google Patents

5-羟色胺受体靶向化合物和方法 Download PDF

Info

Publication number
CN106573872B
CN106573872B CN201580039372.8A CN201580039372A CN106573872B CN 106573872 B CN106573872 B CN 106573872B CN 201580039372 A CN201580039372 A CN 201580039372A CN 106573872 B CN106573872 B CN 106573872B
Authority
CN
China
Prior art keywords
receptor
compound
disorder
hydroxytryptamine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580039372.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106573872A (zh
Inventor
R·G·布思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeastern University Boston
Original Assignee
Northeastern University Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeastern University Boston filed Critical Northeastern University Boston
Publication of CN106573872A publication Critical patent/CN106573872A/zh
Application granted granted Critical
Publication of CN106573872B publication Critical patent/CN106573872B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580039372.8A 2014-05-19 2015-05-19 5-羟色胺受体靶向化合物和方法 Active CN106573872B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000286P 2014-05-19 2014-05-19
US62/000,286 2014-05-19
PCT/US2015/031523 WO2015179366A1 (en) 2014-05-19 2015-05-19 Serotonin receptor-targeting compounds and methods

Publications (2)

Publication Number Publication Date
CN106573872A CN106573872A (zh) 2017-04-19
CN106573872B true CN106573872B (zh) 2021-07-20

Family

ID=54554616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580039372.8A Active CN106573872B (zh) 2014-05-19 2015-05-19 5-羟色胺受体靶向化合物和方法

Country Status (7)

Country Link
US (1) US11021435B2 (enExample)
EP (1) EP3145906B1 (enExample)
JP (1) JP6817073B2 (enExample)
CN (1) CN106573872B (enExample)
BR (1) BR112016027096B1 (enExample)
ES (1) ES2967976T3 (enExample)
WO (1) WO2015179366A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024745A2 (pt) * 2015-05-19 2018-11-13 Univ Northeastern compostos e métodos para modulação de receptores de serotonina na periferia.
CN108794308B (zh) * 2017-04-27 2021-07-20 北京大学深圳研究生院 1,2,3,4-四氢萘类化合物及其制备方法和应用
MX2022004910A (es) * 2019-10-23 2022-08-18 Maplight Therapeutics Inc Metodos de tratamiento de los sintomas del trastorno del espectro autista.
US20230348358A1 (en) * 2020-08-19 2023-11-02 Northeastern University Serotonin Receptor Modulators
WO2023288027A1 (en) * 2021-07-14 2023-01-19 Northeastern University Serotonin 5-ht2a, 5-ht2b, and 5-ht2c receptor inverse agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1183763A (zh) * 1995-05-05 1998-06-03 诺瓦蒂斯有限公司 芳环上带有苯基取代基的四氢萘和它们在治疗癫痫,中风和脑或脊柱创伤中的应用
WO2008154044A1 (en) * 2007-06-15 2008-12-18 University Of Florida Research Foundation Therapeutic compounds and methods of use
CN101636389A (zh) * 2007-02-06 2010-01-27 埃斯蒂文博士实验室股份有限公司 作为5-ht7受体配体的杂环基取代的四氢化萘衍生物
CN101675035A (zh) * 2007-03-28 2010-03-17 埃斯蒂文博士实验室股份有限公司 杂环基-取代的-四氢-萘-胺衍生物、其制备及其作为药物的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632235T2 (de) 1995-10-18 2004-08-26 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
US20030008880A1 (en) * 2001-05-02 2003-01-09 Pfizer Inc. 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity
EP2164324B1 (en) 2007-06-15 2014-08-13 University Of Florida Research Foundation Therapeutic compounds
WO2009061436A1 (en) 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound
EP2427183A4 (en) 2009-05-05 2014-01-08 Univ Florida THERAPEUTIC COMPOUNDS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1183763A (zh) * 1995-05-05 1998-06-03 诺瓦蒂斯有限公司 芳环上带有苯基取代基的四氢萘和它们在治疗癫痫,中风和脑或脊柱创伤中的应用
CN101636389A (zh) * 2007-02-06 2010-01-27 埃斯蒂文博士实验室股份有限公司 作为5-ht7受体配体的杂环基取代的四氢化萘衍生物
CN101675035A (zh) * 2007-03-28 2010-03-17 埃斯蒂文博士实验室股份有限公司 杂环基-取代的-四氢-萘-胺衍生物、其制备及其作为药物的应用
WO2008154044A1 (en) * 2007-06-15 2008-12-18 University Of Florida Research Foundation Therapeutic compounds and methods of use

Also Published As

Publication number Publication date
EP3145906A1 (en) 2017-03-29
BR112016027096B1 (pt) 2023-04-11
WO2015179366A1 (en) 2015-11-26
US20170081273A1 (en) 2017-03-23
JP6817073B2 (ja) 2021-01-20
EP3145906B1 (en) 2023-10-04
CN106573872A (zh) 2017-04-19
JP2017521367A (ja) 2017-08-03
EP3145906A4 (en) 2018-01-24
ES2967976T3 (es) 2024-05-06
US11021435B2 (en) 2021-06-01
BR112016027096A2 (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
CN106573872B (zh) 5-羟色胺受体靶向化合物和方法
US20250163044A1 (en) Compounds
US11352344B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
TW201002701A (en) Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
US20150191481A1 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
US11414406B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
EP3732163A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP3651762A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US12319701B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
US20210188811A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
KR20230026418A (ko) 아릴설포닐 유도체 및 무스카린성 아세틸콜린 수용체 m5 억제제로서의 이의 용도
HK1236024A1 (en) Serotonin receptor-targeting compounds
HK1236024B (en) Serotonin receptor-targeting compounds
ES2892175T3 (es) Moduladores de los receptores NMDA, composiciones que los incluyen y uso de dichos compuestos en el tratamiento de enfermedades que implican al sistema nervioso central
US20230348358A1 (en) Serotonin Receptor Modulators
WO2023150526A1 (en) Competitive and noncompetitive octahydrocyclopenta[c]pyrrole inhibitors of the muscarinic acetylcholine receptor m5
WO2023150525A1 (en) Competitive and noncompetitive piperidine sulfonyl inhibitors of the muscarinic acetylcholine receptor m5
HK40000923A (en) 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant